Galecto Inc (GLTO) Stock Price, Quote & News

Company Profile

Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Industry: Biotechnology

Sector: Healthcare

Phone: 45 70 70 52 10

Website: galecto.com

Address:

Ole Maaloes Vej 3, Copenhagen N, Copenhagen, Denmark

TradingBeasts Oct. 3 at 10:57 PM

Banked up $9.7K on that huge ASTC squeeze today! Made my whole month! 🔥 If you like getting in to those low float squeezers early.. Make sure you drop a FOLLLOW to @MomentumZeus . Great trader for sure 💎 Holding overnight on $CRML $SOPA $BTTC $FEMY $GLTO , hoping for big runs on them

0 · Reply

PremarketAnalysis Oct. 3 at 10:25 PM

$GLTO flipped with algo reversal after breakdown.. support rests 4.01/3.84, needs reclaim over 4.46 to open room back toward highs.. Momentum Feed: https://premarketanalysis.com/#momentum=GLTO

0 · Reply

topstockalerts Oct. 3 at 9:23 PM

After Hours Top Gainers PT2 $GLTO $CETY $RVPH $ARBKL $TDIC

1 · Reply

stockWare Oct. 3 at 9:13 PM

$YAAS regained Nasdaq compliance today, should be enough to move this type of stock dramatically. $SABS $TBH $GLTO

0 · Reply

caprihunter Oct. 3 at 8:21 PM

$CETY Clean Energy Technologies (Nasdaq: CETY) announced on October 3, 2025 that its Clean Cycle II™ Organic Rankine Cycle (ORC) has been deployed in Martin, Tennessee. RPG Energy Group led project development and integration for a Fortune 100 industrial manufacturing client, installing a waste-heat-to-power system that converts industrial waste heat into usable electricity. The release positions the Martin project as one of the first U.S. industrial ORC deployments and a replicable model for reducing energy costs and improving sustainability. $IMG $MIGI $CLNN $GLTO FORTUNE 100 INDUSTRIAL MANUFACTURING CLIENT LET'S GO

1 · Reply

DaBullRunner Oct. 3 at 8:17 PM

$GLTO there it goes… MSPR adding for the BIG run 🚨🚨🚨 WATCH AND LEARN LIKE HIM👇

0 · Reply

caprihunter Oct. 3 at 8:16 PM

2 · Reply

ATerragna Oct. 3 at 8:09 PM

$GLTO

0 · Reply

Investor1337 Oct. 3 at 8:09 PM

$GLTO 10x soon

0 · Reply

TradingBeasts Oct. 3 at 8:03 PM

$GLTO moving p

0 · Reply

Galecto Reports Second Quarter 2025 Operating and Financial Results

May 8, 2025, 4:30 PM EDT - 5 months ago

Galecto Reports First Quarter 2025 Operating and Financial Results

Mar 19, 2025, 4:45 PM EDT - 7 months ago

Galecto Reports Full-Year 2024 Financial Results

Feb 6, 2025, 8:00 AM EST - 8 months ago

Galecto to Participate in Upcoming Investor Conferences

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Galecto Reports Third Quarter 2024 Financial Results

Oct 15, 2024, 8:30 AM EDT - 1 year ago

Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler

Oct 7, 2024, 8:45 AM EDT - 1 year ago

Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

Aug 28, 2024, 9:00 AM EDT - 1 year ago

Galecto Announces Reverse Stock Split

May 1, 2024, 4:01 PM EDT - 1 year ago

Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab

Dec 21, 2023, 4:05 PM EST - 1 year ago

Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial

Sep 26, 2023, 4:01 PM EDT - 2 years ago

Galecto Announces Plans to Explore Strategic Alternatives

Sep 14, 2023, 8:15 AM EDT - 2 years ago

Galecto Biotech Collapse: Opportunity For Galectin Therapeutics

GALT

Aug 31, 2023, 11:00 AM EDT - 2 years ago

Galecto to Present at Investor Conferences in September

Aug 15, 2023, 8:39 AM EDT - 2 years ago

Galecto shares drop 65% as biotech halts development of lung-disease treatment

Aug 15, 2023, 7:55 AM EDT - 2 years ago

Galecto to discontinue development of lung disease treatment

Aug 15, 2023, 7:30 AM EDT - 2 years ago

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

Jul 31, 2023, 4:05 PM EDT - 2 years ago

Galecto Reports Second Quarter Operating and Financial Results

Jun 20, 2023, 8:58 AM EDT - 2 years ago

Galecto Set to Join Russell Microcap® Index

May 30, 2023, 8:00 AM EDT - 2 years ago

Galecto to Present at the Upcoming Jefferies Healthcare Conference

May 23, 2023, 8:30 AM EDT - 2 years ago

Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis

May 17, 2023, 4:01 PM EDT - 2 years ago

Galecto to Present Poster at Upcoming ATS 2023 International Conference

Apr 28, 2023, 8:00 AM EDT - 2 years ago

Galecto Reports First Quarter Operating and Financial Results

Apr 18, 2023, 7:01 PM EDT - 2 years ago

Galecto: Promising Pipeline And Excellent Risk-Reward

Apr 13, 2023, 8:30 AM EDT - 2 years ago

Galecto to Present Two Posters at AACR Annual Meeting 2023

Mar 9, 2023, 7:00 AM EST - 2 years ago

Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022

Mar 2, 2023, 4:05 PM EST - 2 years ago

Galecto to Participate in Oppenheimer's 33rd Annual Healthcare Conference

Feb 1, 2023, 8:00 AM EST - 2 years ago

Galecto to Participate in SVB Securities Global Biopharma Conference

Dec 7, 2022, 4:05 PM EST - 3 years ago

Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting

Nov 8, 2022, 9:15 AM EST - 3 years ago

Galecto Reports Third Quarter Operating and Financial Results

Nov 8, 2022, 6:00 AM EST - 3 years ago

Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients

Nov 3, 2022, 8:00 AM EDT - 3 years ago

Galecto to Participate in Jefferies London Healthcare Conference

Oct 31, 2022, 8:00 AM EDT - 3 years ago

Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting® 2022

Oct 19, 2022, 8:00 AM EDT - 3 years ago

Galecto's Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute

Oct 17, 2022, 6:00 AM EDT - 3 years ago

Galecto to Host Virtual Investor Event and Webcast to Review Topline Data from GULLIVER-2 Trial on Tuesday, November 8, 2022

Sep 29, 2022, 10:11 AM EDT - 3 years ago

Galecto ($GLTO) Phase 2a Trial Reduces Fibrosis of Bone Marrow in Patients with Myelofibrosis

Sep 29, 2022, 6:00 AM EDT - 3 years ago

GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target

Sep 6, 2022, 8:30 AM EDT - 3 years ago

Galecto to Participate at H.C. Wainwright 24th Annual Global Investment Conference

Aug 29, 2022, 8:30 AM EDT - 3 years ago

Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal

May 31, 2022, 8:30 AM EDT - 3 years ago

Galecto to Participate at Jefferies Healthcare Conference

May 26, 2022, 8:30 AM EDT - 3 years ago

Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting

Apr 26, 2022, 8:30 AM EDT - 3 years ago

Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF

Mar 29, 2022, 8:30 AM EDT - 3 years ago

Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Feb 17, 2022, 5:00 PM EST - 3 years ago

Galecto Reports Financial Results for the Year Ended December 31, 2021

Jan 27, 2022, 7:00 AM EST - 4 years ago

Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care

Dec 13, 2021, 8:00 AM EST - 4 years ago

Galecto Announces Positive Preliminary Results for Oral Galectin-3 Inhibitor GB1211 in Part 1 of its Phase 1b/2a Liver Cirrhosis Trial

Nov 2, 2021, 11:26 AM EDT - 4 years ago

Galecto To Test GB1211 Combined with Roche's Tecentriq In First Line Lung Cancer Setting

Nov 2, 2021, 8:00 AM EDT - 4 years ago

Galecto Announces Clinical Collaboration with Roche for Phase 2 Trial of GB1211 in Combination with Atezolizumab in First Line Non-Small-Cell Lung Cancer

Oct 26, 2021, 8:00 AM EDT - 4 years ago

Galecto to Present at Upcoming Investor Conferences

Sep 15, 2021, 8:30 AM EDT - 4 years ago

Galecto to Present at 2021 Cantor Virtual Global Healthcare Conference

TradingBeasts Oct. 3 at 10:57 PM

0 · Reply

PremarketAnalysis Oct. 3 at 10:25 PM

$GLTO flipped with algo reversal after breakdown.. support rests 4.01/3.84, needs reclaim over 4.46 to open room back toward highs.. Momentum Feed: https://premarketanalysis.com/#momentum=GLTO

0 · Reply

topstockalerts Oct. 3 at 9:23 PM

After Hours Top Gainers PT2 $GLTO $CETY $RVPH $ARBKL $TDIC

1 · Reply

stockWare Oct. 3 at 9:13 PM

$YAAS regained Nasdaq compliance today, should be enough to move this type of stock dramatically. $SABS $TBH $GLTO

0 · Reply

caprihunter Oct. 3 at 8:21 PM

1 · Reply

DaBullRunner Oct. 3 at 8:17 PM

$GLTO there it goes… MSPR adding for the BIG run 🚨🚨🚨 WATCH AND LEARN LIKE HIM👇

0 · Reply

caprihunter Oct. 3 at 8:16 PM

2 · Reply

ATerragna Oct. 3 at 8:09 PM

$GLTO

0 · Reply

Investor1337 Oct. 3 at 8:09 PM

$GLTO 10x soon

0 · Reply

TradingBeasts Oct. 3 at 8:03 PM

$GLTO moving p

0 · Reply

skyrockets_Inc Oct. 3 at 2:14 PM

$BOLT Data was originally slated for '1H 2026' now it's 'Q3 2026' so it's really only a quarter delay. Cash burn / qtr was 10M, 50% RIF will significantly reduce cash burn. 38M stockholder equity end of June 30, puts this at about 30M intrinsic value today or approx $15/share. Giving ZERO value to any assets or partnerships w/ big pharma (Genmab / Toray). Tang owns ~9% . I fully expect w/ this great value position, low float (~1.92M shares), and institutional interest that this will either get a TANG BANG buyout offer soon or will have a low-float $GLTO style pump. Either way, rocketships will be launching soon!

0 · Reply

AtlasFrontier Oct. 3 at 3:46 AM

I found a stock that is about to absolutely explode Tomorrow. Check out GIPR 🚨🚀 GIPR 🚀🔥 🔹 Early lease extension w/ Best Buy thru 2032 + rent bump 6.5% 📈 🔹 Revenue up ~28% YoY to $9.7M 💰 🔹 Exploring strategic alternatives – sale/merger/recap possibilities 🧐 🔹 High occupancy & investment-grade tenants keep cash flowing 🏢 keeping eyes $CIFR $LEDS $GLTO $LIXT

0 · Reply

FaReSx99 Oct. 2 at 7:54 PM

$GLTO

0 · Reply

FaReSx99 Oct. 2 at 3:57 PM

$GLTO Come on wake up the road is open 💥🔥

0 · Reply

Investor1337 Oct. 2 at 3:19 PM

$GLTO news any day

0 · Reply

FaReSx99 Oct. 2 at 3:00 PM

$GLTO 🔥🔥

0 · Reply

FaReSx99 Oct. 2 at 2:56 PM

$GLTO

0 · Reply

skyrockets_Inc Sep. 30 at 4:49 PM

$BOLT Agreed. This is the next low-float bio play that will have a $GLTO move . Way better company financials and fundamentals w/ one drug in trial and the other being partnered. Trading at 1/4 cash value w/ the smallest float I've seen in a while.

0 · Reply

jamesownsu Sep. 30 at 3:00 PM

$GLTO pump and dump

0 · Reply

BucketzUp Sep. 29 at 1:55 AM

$MRM $NITO $WAI $VMAR $GLTO

0 · Reply

Modsiu Sep. 27 at 5:16 PM

$BOXL $OPEN $GLTO $SPRC

0 · Reply

Modsiu Sep. 27 at 1:08 AM

$BOXL $TNFA $SPRC $AGRI $GLTO

0 · Reply

Market Cap	5.02M
Revenue (ttm)	0.00
Net Income (ttm)	-21.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	738,000
Avg Vol	1,286,826
Day's Range	N/A - N/A
Shares Out	1.33M
Stochastic %K	19%
Beta	1.38
Analysts	Hold
Price Target	$6.00